Display options
Cite
Kim MA, Jang H, Choi NR, et al. Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. J Hepatocell Carcinoma. 2021;8:1565-1577doi: 10.2147/JHC.S335879.
Kim, M. A., Jang, H., Choi, N. R., Nam, J. Y., Lee, Y. B., Cho, E. J., Lee, J. H., Yu, S. J., Kim, H. C., Chung, J. W., Yoon, J. H., & Kim, Y. J. (2021). Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. Journal of hepatocellular carcinoma, 81565-1577. https://doi.org/10.2147/JHC.S335879
Kim, Minseok Albert, et al. "Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study." Journal of hepatocellular carcinoma vol. 8 (2021): 1565-1577. doi: https://doi.org/10.2147/JHC.S335879
Kim MA, Jang H, Choi NR, Nam JY, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim HC, Chung JW, Yoon JH, Kim YJ. Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. J Hepatocell Carcinoma. 2021 Dec 07;8:1565-1577. doi: 10.2147/JHC.S335879. eCollection 2021. PMID: 34909425; PMCID: PMC8665867.
Copy Download .nbib Format: NLM
Share it on

J Hepatocell Carcinoma. 2021 Dec 07;8:1565-1577. doi: 10.2147/JHC.S335879. eCollection 2021.

Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study.

Journal of hepatocellular carcinoma

Minseok Albert Kim, Heejoon Jang, Na Ryung Choi, Joon Yeul Nam, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Hyo-Cheol Kim, Jin Wook Chung, Jung-Hwan Yoon, Yoon Jun Kim

Affiliations

  1. Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
  2. Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.

PMID: 34909425 PMCID: PMC8665867 DOI: 10.2147/JHC.S335879

Abstract

BACKGROUND: Both trans-arterial radioembolization (TARE) and conventional trans-arterial chemoembolization (TACE) can effectively control hepatocellular carcinoma (HCC) in patients who are not suitable for curative resection. This study compared the effectiveness of TARE and conventional TACE as the initial trans-arterial treatment for hepatocellular carcinoma (HCC) assessed by tumor response and clinical outcomes.

MATERIAL AND METHODS: Data were retrospectively analyzed the propensity score-matched cohort for overall survival (OS), progression-free survival (PFS), and intrahepatic PFS in patients who have received TARE or TACE as the first HCC treatment from March 2012 to December 2017.

RESULTS: A total of 138 patients initially treated with TARE (n = 54) or TACE (n = 84) was included in this study. Of 138 patients, median age was 59 years and the mean follow-up period was 27.6 months. TARE showed better OS (hazard ratio [HR] = 0.54, 95% confidence interval [CI] = 0.31-0.92, log-rank

CONCLUSION: TARE as initial trans-arterial treatment is associated with better clinical outcomes such as longer OS compared with TACE in patients with HCC.

© 2021 Kim et al.

Keywords: brachytherapy; embolization; liver neoplasms; yttrium radioisotopes

Conflict of interest statement

All authors have no conflicts of interest to disclose.

Publication Types